Briefing
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Fixed-duration (not MRD-guided) ibrutinib-venetoclax cohort. In the all-treated population, CR 55% (95% CI 48-63); best uMRD 77% (PB) and 60% (BM); 24-month PFS 95% and OS 98%. Level 2.
- Design: paper
- Assay: uMRD in PB and BM after fixed-duration I+V (not MRD-guided in this cohort)